Resveratrol inhibits NPC apoptosis in a dose-dependent manner by inhibiting activation of the ERK1/2 signalling pathway, resulting in reduced Bax and caspase-3/cleaved caspase-3, significantly increased Bcl-2, and significantly decreased Bax/Bcl-2 ratios (Zhang et al., 2018b). The gene discussed is BCL2; the disease is nasopharyngeal carcinoma.